Abstract
Intranasal ketamine may reduce opioid requirements in cancer-related pain, but adverse effects can limit tolerability. Future research should identify high-risk patients and develop risk mitigation strategies.
Affiliated Institutions
Related Publications
CDC Clinical Practice Guideline for Prescribing Opioids for Pain<b>—</b>United States, 2022
This guideline provides recommendations for clinicians providing pain care, including those prescribing opioids, for outpatients aged ≥18 years. It updates the CDC Guideline for...
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Cellular senescence is a stable cell cycle arrest that can be triggered in normal cells in response to various intrinsic and extrinsic stimuli, as well as developmental signals....
Hazards of heavy metal contamination
The main threats to human health from heavy metals are associated with exposure to lead, cadmium, mercury and arsenic. These metals have been extensively studied and their effec...
International guidelines for groin hernia management
IntroductionWorldwide, more than 20 million patients undergo groin hernia repair annually. The many different approaches, treatment indications and a significant array of techni...
Symptomatic Intracerebral Hemorrhage following Thrombolytic Therapy for Acute Ischemic Stroke: A Review of the Risk Factors
<i>Background:</i> Symptomatic intracerebral hemorrhage (SICH) following thrombolytic therapy for acute ischemic stroke is associated with a high rate of morbidity a...
Publication Info
- Year
- 2025
- Type
- article
- Pages
- 1-5
- Citations
- 0
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
0
OpenAlex
Cite This
Justine W. Welsh,
Ali John Zarrabi,
Vinita Singh
(2025).
Intranasal ketamine for chronic cancer-related pain in the outpatient setting: a double-edged sword.
Pain Management
, 1-5.
https://doi.org/10.1080/17581869.2025.2599730
Identifiers
- DOI
- 10.1080/17581869.2025.2599730